stockrowLegend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +126.1%
- Free cash flow
- −26.8%
- Total debt
- −49.6%
Quarter to June 2026, against a year earlier
Follow LEGN
Alert me
Legend Biotech Corporation Sponsored ADR (LEGN) P/B ratio
As of 6 November 2026, Legend Biotech Corporation Sponsored ADR (LEGN) trades at a P/B ratio of 3.6×. Over the past ten years it has ranged from 0.0× (June 2020) to 36.6× (October 2021); the current reading is higher than 9% of that period. That is above the Biotechnology industry median of 2.1× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 4.0× | (30.07%) |
| FY2024 | 5.7× | (33.31%) |
| FY2023 | 8.6× | (19.02%) |
| FY2022 | 10.6× | 23.53% |
| FY2021 | 8.6× | (27.80%) |
| FY2020 | 11.9× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 4.4× | 26.93% |
| Mar 2026 | 3.5× | (13.47%) |
| Dec 2025 | 4.0× | (32.84%) |
| Sep 2025 | 6.0× | (5.66%) |
| 23 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| CRSP CRISPR Therapeutics AG compare | 2.9× |
| EWTX Edgewise Therapeutics, Inc. compare | 3.0× |
| LEGN Legend Biotech Corporation Sponsored ADR | 3.6× |
| DNTH Dianthus Therapeutics, Inc. compare | 4.0× |
| DFTX Definium Therapeutics, Inc. compare | 4.0× |
| RLAY Relay Therapeutics, Inc. compare | 4.9× |
| COGT Cogent Biosciences, Inc. compare | 11.6× |
| ERAS Erasca, Inc. compare | 12.3× |
| TVTX Travere Therapeutics, Inc. compare | 207× |
| Biotechnology industry median | 2.1× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on LEGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement